[Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results)].

E I Gusev Mikhail Yu Martynov N A Shamalov Elena B Yarovaya M P Semenov A M Semenov A A Orlovsky Vladimir A Kutsenko A A Nikonov S B Aksentiev D S Yunevich A M Alasheev O V Androfagina V V Bobkov K V Choroshavina V I Gorbachev I V Korobeynikov I V Greshnova A V Dobrovolskiy U A Elemanov N V Zhukovskaya S A Zakharov A N Chirkov L L Korsunskaya V N Nesterova A A Nikonova A A Nizov A I Girivenko E A Ponomarev D V Popov S A Pribylov A S Semikhin L V Timchenko O N Jadan S A Fedyanin Zh Yu Chefranova Yu A Lykov S E Chuprina A A Vorobev A I Archakov Sergey S Markin

Published in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)

The presented results of the FRIDA trial are the first in the world to use a drug based on NS in patients with IS. It has been shown that a single bolus (within 10 s) administration of NS at a standard dose of 10 mg, regardless of body weight, allows to conduct fast, effective and safe thrombolytic therapy in patients with IS within 4.5 h after symptom onset. In further clinical tials of NS, it is planned to expand the therapeutic window beyond 4.5 h after symptom onset in patients with IS.

Keyphrases